Inhibition by 5'-methylthioadenosine of cell growth and tyrosine kinase activity stimulated by fibroblast growth factor receptor in human gliomas.
Stimulation of three human glioma cell lines with basic fibroblast growth factor (bFGF) led to the enhancement of cell growth and the rapid tyrosine phosphorylation of cellular proteins, including major substrates of 90 kD. A methyltransferase inhibitor, 5'-methylthioadenosine (MTA), inhibited dose dependently the bFGF-stimulated cell growth and protein tyrosine phosphorylation in glioma cells by blocking both receptor autophosphorylation and substrate phosphorylation, as shown by immunoblotting with antiphosphotyrosine antibodies and cross-linking bFGF to receptors. The antiproliferative activity of MTA correlated quantitatively with its potency as an inhibitor of bFGF-stimulated protein tyrosine kinase activity. The methyltransferase inhibitor MTA had no effect on either epidermal growth factor- or platelet-derived growth factor-stimulated protein tyrosine phosphorylation in glioma cells, but inhibited specifically bFGF-stimulated protein tyrosine kinase activity. The concentration of MTA required for inhibition of protein methylation correlated well with the concentration required for inhibition of bFGF-stimulated cell growth and protein tyrosine phosphorylation. Because MTA had no effect on numbers and dissociation constants of high- and low-affinity bFGF receptors, the inhibition of bFGF-stimulated bFGF receptor tyrosine kinase activity is not likely to be the result of a reduction in bFGF receptor and bFGF binding capacity. In fact, MTA delayed and reduced the internalization and nuclear translocation of bFGF, and the internalized bFGF was submitted to a limited proteolysis that converted it to lower molecular peptides whose presence remained for at least 22 hours. The effect of MTA on bFGF-stimulated tyrosine phosphorylation was immediate and readily reversible.
Miyaji
K
K
Department of Neurosurgery, Hyogo College of Medicine, Japan.
Tani
E
E
Nakano
A
A
Ikemoto
H
H
Kaba
K
K
D000906:Antibodies; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002467:Cell Nucleus / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D003432:Cross-Linking Reagents; D003839:Deoxyadenosines / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000187:drug effects; D016222:Fibroblast Growth Factor 2 / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology; D005909:Glioblastoma / Q000201:enzymology / Q000378:metabolism / Q000473:pathology; D005910:Glioma / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology*; D006801:Humans; D015151:Immunoblotting; D007457:Iodine Radioisotopes; D008780:Methyltransferases / Q000037:antagonists & inhibitors*; D009363:Neoplasm Proteins / Q000187:drug effects; D010766:Phosphorylation / Q000187:drug effects; D019000:Phosphotyrosine; D010982:Platelet-Derived Growth Factor / Q000187:drug effects; D011233:Precipitin Tests; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D017468:Receptors, Fibroblast Growth Factor / Q000037:antagonists & inhibitors / Q000187:drug effects*; D013872:Thionucleosides / Q000008:administration & dosage / Q000494:pharmacology*; D014443:Tyrosine / Q000031:analogs & derivatives / Q000032:analysis
D000906:Antibodies; D003432:Cross-Linking Reagents; D003839:Deoxyadenosines; D007457:Iodine Radioisotopes; D009363:Neoplasm Proteins; D010982:Platelet-Derived Growth Factor; D017468:Receptors, Fibroblast Growth Factor; D013872:Thionucleosides; D016222:Fibroblast Growth Factor 2; D019000:Phosphotyrosine; D014443:Tyrosine; D004815:Epidermal Growth Factor; C008500:5'-methylthioadenosine; D008780:Methyltransferases; D011505:Protein-Tyrosine Kinases